A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor

Xiaofeng He, Moon Hee Na, Jin Sook Kim, Ga Young Lee, Jae Yong Park, Allan S. Hoffman, Ju Ock Nam, Su Eun Han, Ga Yong Sim, Yu Kyoung Oh, In-San Kim, Byung Heon Lee

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Targeted delivery of imaging agents and therapeutics to tumors would provide early detection and increased therapeutic efficacy against cancer. Here we have screened a phage-displayed peptide library to identify peptides that selectively bind to lung tumor cells. Evaluation of individual phage clones after screening revealed that a phage clone displaying the CSNIDARAC peptide bound to H460 lung tumor cells at higher extent than other phage clones. The synthetic CSNIDARAC peptide strongly bound to H460 cells and was efficiently internalized into the cells, while little binding of a control peptide was seen. It also preferentially bound to other lung tumor cell lines as compared to cells of different tumor types. In vivo imaging of lung tumor was achieved by homing of fluorescence dye-labeled CSNIDARAC peptide to the tumor after intravenous injection into mice. Ex vivo imaging and microscopic analysis of isolated organs further demonstrated the targeting of CSNIDARAC peptide to tumor. The CSNIDARAC peptide-targeted and doxorubicin-loaded liposomes inhibited the tumor growth more efficiently than untargeted liposomes or free doxorubicin. In vivo imaging of fluorescence dye-labeled liposomes demonstrated selective homing of the CSNIDARAC-liposomes to tumor. In the same context, higher levels of doxorubicin and apoptosis in tumor tissue were observed when treated with the targeted liposomes than untargeted liposomes or free doxorubicin. These results suggest that the CSNIDARAC peptide is a promising targeting probe that is able to direct imaging agents and therapeutics to lung tumor.

Original languageEnglish
Pages (from-to)430-438
Number of pages9
JournalMolecular Pharmaceutics
Volume8
Issue number2
DOIs
Publication statusPublished - 2011 Apr 4
Externally publishedYes

Fingerprint

Lung
Peptides
Liposomes
Neoplasms
Bacteriophages
Doxorubicin
Clone Cells
liposomal doxorubicin
Coloring Agents
Peptide Library
Optical Imaging
Tumor Cell Line
Intravenous Injections
Therapeutics
Fluorescence
Apoptosis
Growth

Keywords

  • drug delivery
  • imaging
  • liposomal doxorubicin
  • lung tumor
  • peptide probe
  • phage display

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

He, X., Na, M. H., Kim, J. S., Lee, G. Y., Park, J. Y., Hoffman, A. S., ... Lee, B. H. (2011). A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor. Molecular Pharmaceutics, 8(2), 430-438. https://doi.org/10.1021/mp100266g

A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor. / He, Xiaofeng; Na, Moon Hee; Kim, Jin Sook; Lee, Ga Young; Park, Jae Yong; Hoffman, Allan S.; Nam, Ju Ock; Han, Su Eun; Sim, Ga Yong; Oh, Yu Kyoung; Kim, In-San; Lee, Byung Heon.

In: Molecular Pharmaceutics, Vol. 8, No. 2, 04.04.2011, p. 430-438.

Research output: Contribution to journalArticle

He, X, Na, MH, Kim, JS, Lee, GY, Park, JY, Hoffman, AS, Nam, JO, Han, SE, Sim, GY, Oh, YK, Kim, I-S & Lee, BH 2011, 'A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor', Molecular Pharmaceutics, vol. 8, no. 2, pp. 430-438. https://doi.org/10.1021/mp100266g
He, Xiaofeng ; Na, Moon Hee ; Kim, Jin Sook ; Lee, Ga Young ; Park, Jae Yong ; Hoffman, Allan S. ; Nam, Ju Ock ; Han, Su Eun ; Sim, Ga Yong ; Oh, Yu Kyoung ; Kim, In-San ; Lee, Byung Heon. / A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor. In: Molecular Pharmaceutics. 2011 ; Vol. 8, No. 2. pp. 430-438.
@article{4d691de20f7840a59ebe4e8a1b79bb40,
title = "A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor",
abstract = "Targeted delivery of imaging agents and therapeutics to tumors would provide early detection and increased therapeutic efficacy against cancer. Here we have screened a phage-displayed peptide library to identify peptides that selectively bind to lung tumor cells. Evaluation of individual phage clones after screening revealed that a phage clone displaying the CSNIDARAC peptide bound to H460 lung tumor cells at higher extent than other phage clones. The synthetic CSNIDARAC peptide strongly bound to H460 cells and was efficiently internalized into the cells, while little binding of a control peptide was seen. It also preferentially bound to other lung tumor cell lines as compared to cells of different tumor types. In vivo imaging of lung tumor was achieved by homing of fluorescence dye-labeled CSNIDARAC peptide to the tumor after intravenous injection into mice. Ex vivo imaging and microscopic analysis of isolated organs further demonstrated the targeting of CSNIDARAC peptide to tumor. The CSNIDARAC peptide-targeted and doxorubicin-loaded liposomes inhibited the tumor growth more efficiently than untargeted liposomes or free doxorubicin. In vivo imaging of fluorescence dye-labeled liposomes demonstrated selective homing of the CSNIDARAC-liposomes to tumor. In the same context, higher levels of doxorubicin and apoptosis in tumor tissue were observed when treated with the targeted liposomes than untargeted liposomes or free doxorubicin. These results suggest that the CSNIDARAC peptide is a promising targeting probe that is able to direct imaging agents and therapeutics to lung tumor.",
keywords = "drug delivery, imaging, liposomal doxorubicin, lung tumor, peptide probe, phage display",
author = "Xiaofeng He and Na, {Moon Hee} and Kim, {Jin Sook} and Lee, {Ga Young} and Park, {Jae Yong} and Hoffman, {Allan S.} and Nam, {Ju Ock} and Han, {Su Eun} and Sim, {Ga Yong} and Oh, {Yu Kyoung} and In-San Kim and Lee, {Byung Heon}",
year = "2011",
month = "4",
day = "4",
doi = "10.1021/mp100266g",
language = "English",
volume = "8",
pages = "430--438",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor

AU - He, Xiaofeng

AU - Na, Moon Hee

AU - Kim, Jin Sook

AU - Lee, Ga Young

AU - Park, Jae Yong

AU - Hoffman, Allan S.

AU - Nam, Ju Ock

AU - Han, Su Eun

AU - Sim, Ga Yong

AU - Oh, Yu Kyoung

AU - Kim, In-San

AU - Lee, Byung Heon

PY - 2011/4/4

Y1 - 2011/4/4

N2 - Targeted delivery of imaging agents and therapeutics to tumors would provide early detection and increased therapeutic efficacy against cancer. Here we have screened a phage-displayed peptide library to identify peptides that selectively bind to lung tumor cells. Evaluation of individual phage clones after screening revealed that a phage clone displaying the CSNIDARAC peptide bound to H460 lung tumor cells at higher extent than other phage clones. The synthetic CSNIDARAC peptide strongly bound to H460 cells and was efficiently internalized into the cells, while little binding of a control peptide was seen. It also preferentially bound to other lung tumor cell lines as compared to cells of different tumor types. In vivo imaging of lung tumor was achieved by homing of fluorescence dye-labeled CSNIDARAC peptide to the tumor after intravenous injection into mice. Ex vivo imaging and microscopic analysis of isolated organs further demonstrated the targeting of CSNIDARAC peptide to tumor. The CSNIDARAC peptide-targeted and doxorubicin-loaded liposomes inhibited the tumor growth more efficiently than untargeted liposomes or free doxorubicin. In vivo imaging of fluorescence dye-labeled liposomes demonstrated selective homing of the CSNIDARAC-liposomes to tumor. In the same context, higher levels of doxorubicin and apoptosis in tumor tissue were observed when treated with the targeted liposomes than untargeted liposomes or free doxorubicin. These results suggest that the CSNIDARAC peptide is a promising targeting probe that is able to direct imaging agents and therapeutics to lung tumor.

AB - Targeted delivery of imaging agents and therapeutics to tumors would provide early detection and increased therapeutic efficacy against cancer. Here we have screened a phage-displayed peptide library to identify peptides that selectively bind to lung tumor cells. Evaluation of individual phage clones after screening revealed that a phage clone displaying the CSNIDARAC peptide bound to H460 lung tumor cells at higher extent than other phage clones. The synthetic CSNIDARAC peptide strongly bound to H460 cells and was efficiently internalized into the cells, while little binding of a control peptide was seen. It also preferentially bound to other lung tumor cell lines as compared to cells of different tumor types. In vivo imaging of lung tumor was achieved by homing of fluorescence dye-labeled CSNIDARAC peptide to the tumor after intravenous injection into mice. Ex vivo imaging and microscopic analysis of isolated organs further demonstrated the targeting of CSNIDARAC peptide to tumor. The CSNIDARAC peptide-targeted and doxorubicin-loaded liposomes inhibited the tumor growth more efficiently than untargeted liposomes or free doxorubicin. In vivo imaging of fluorescence dye-labeled liposomes demonstrated selective homing of the CSNIDARAC-liposomes to tumor. In the same context, higher levels of doxorubicin and apoptosis in tumor tissue were observed when treated with the targeted liposomes than untargeted liposomes or free doxorubicin. These results suggest that the CSNIDARAC peptide is a promising targeting probe that is able to direct imaging agents and therapeutics to lung tumor.

KW - drug delivery

KW - imaging

KW - liposomal doxorubicin

KW - lung tumor

KW - peptide probe

KW - phage display

UR - http://www.scopus.com/inward/record.url?scp=79953806936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953806936&partnerID=8YFLogxK

U2 - 10.1021/mp100266g

DO - 10.1021/mp100266g

M3 - Article

C2 - 21222482

AN - SCOPUS:79953806936

VL - 8

SP - 430

EP - 438

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 2

ER -